Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study (Q80100963)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409969%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

title

Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409969%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference

Alex Chang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409969%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Purvish Parikh

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409969%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Sumitra Thongprasert

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409969%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Eng Huat Tan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409969%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Reury-Perng Perng

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409969%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Domingo Ganzon

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409969%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Chih-Hsin Yang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409969%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Chao-Jung Tsao

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409969%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Claire Watkins

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409969%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Nick Botwood

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409969%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Nick Thatcher

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409969%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

1 October 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409969%20AND%20SRC:MED&resulttype=core&format=json

Journal of Thoracic Oncology

28 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409969%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409969%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409969%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

847-855

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409969%20AND%20SRC:MED&resulttype=core&format=json

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592.

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

Measuring Response in Solid Tumors: Comparison of RECIST and WHO Response Criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1556-0864%2815%2930415-9

7 January 2021

10.1016/S1556-0864(15)30415-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17409969%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

1 reference